Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A signed informed consent document.~* Male and non-pregnant, non-lactating female subjects.~* Female subjects must be post menopausal, surgically sterile, or practicing an effective method of birth control and continue to do so throughout the trial.~* At least 18 years of age.~* Have chronic malignant tumor-related pain~* Are opioid-naïve or have been pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.~* Have a mean pain intensity of at least 5 points on an 11-point Numeric Rating Scale (where 0 indicates no pain and 10 indicates worst possible pain).~* Have an expected course of the disease such that the pain that will permit compliance with the trial protocol over the entire trial period.~Exclusion Criteria:~* Have a life-long history of seizure disorder or epilepsy.~* Have had any of the following within one year: mild/moderate traumatic brain injury, stroke, and transient ischemic attack.~* Have had severe traumatic brain injury within 15 years (consisting of ≥ 1 of the following: brain contusion, intracranial hematoma, and either unconsciousness or post-traumatic amnesia lasting for more than 24 hours) or residual sequelae suggesting transient changes in consciousness.~* Have a known history and/or presence of cerebral metastases.~* Have moderately or severely impaired hepatic function.~* Have laboratory values reflecting inadequate hepatic function.~* Have thrombopenia, leucopenia or hypercalcemia~* Have severely impaired renal function.~* Having uncontrolled hypertension~* Having clinically relevant history of hypersensitivity, allergy or contraindications to morphine or any of the excipients.~* Have chronic hepatitis B or hepatitis C, or Human Immunodeficiency Virus (HIV).~* Subjects currently undergoing the following concomitant therapy: radiotherapy, pain inducing chemotherapy, anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine re-uptake inhibitors (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial. Selective serotonin re-uptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the trial at an unchanged dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Matching Placebo (Type: PLACEBO_COMPARATOR): Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
- Morphine Controlled Release (Type: ACTIVE_COMPARATOR): Oral Morphine 45 mg to 90 mg twice daily.
- Tapentadol Extended Release (Type: EXPERIMENTAL): Oral Tapentadol 100 mg to 250 mg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).